0001209191-19-018091.txt : 20190308
0001209191-19-018091.hdr.sgml : 20190308
20190308161700
ACCESSION NUMBER: 0001209191-19-018091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190306
FILED AS OF DATE: 20190308
DATE AS OF CHANGE: 20190308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PASSERI DANIEL R
CENTRAL INDEX KEY: 0001190121
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38327
FILM NUMBER: 19669288
MAIL ADDRESS:
STREET 1: C/O CURIS INC
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cue Biopharma, Inc.
CENTRAL INDEX KEY: 0001645460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473324577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-949-2680
MAIL ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Imagen Biopharma, Inc.
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-06
0
0001645460
Cue Biopharma, Inc.
CUE
0001190121
PASSERI DANIEL R
21 ERIE STREET
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
47600
D
Stock Option (right to buy)
6.42
2019-03-06
4
A
0
125000
0.00
A
2029-03-06
Common Stock
125000
125000
D
Stock Option (right to buy)
11.54
2019-03-06
4
A
0
100000
0.00
A
2025-07-23
Common Stock
100000
100000
D
This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019.
Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions.
/s/ Daniel Passeri by Mark Busch, as attorney-in-fact
2019-03-08